High impact
Newsletter Vol. 32, No.07
New Jersey Medicaid·Identified Jun 20, 2026
HCPCS Q0181 is officially defined as "Unspecified oral dosage form, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for a iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen." HCPCS Q0181 is referenced in 1 tracked payer policy change from New Jersey Medicaid. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS Q0181 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.
Related
Get alerts for changes like this
Save a search and receive a daily digest whenever a new policy change matches your filters.